Connor, Clark & Lunn Investment Management Ltd. Harmony Biosciences Holdings, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $21.1 Billion
- Q1 2025
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 114,210 shares of HRMY stock, worth $4.05 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
114,210Holding current value
$4.05 Million% of portfolio
0.02%Shares
3 transactions
Others Institutions Holding HRMY
# of Institutions
278Shares Held
44.8MCall Options Held
130KPut Options Held
46.5K-
Valor Management LLC Chicago, IL6.62MShares$234 Million91.68% of portfolio
-
Black Rock Inc. New York, NY5.84MShares$207 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.7MShares$166 Million0.0% of portfolio
-
State Street Corp Boston, MA1.58MShares$55.9 Million0.0% of portfolio
-
American Century Companies Inc Kansas City, MO1.29MShares$45.6 Million0.03% of portfolio
About Harmony Biosciences Holdings, Inc.
- Ticker HRMY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,161,400
- Market Cap $2.1B
- Description
- Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...